Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Apr 15, 2010

Premium

Silence Therapeutics said it has named Max Herrmann as its new CFO.

Herrmann was most recently CFO of Intercytex, a public company focused on regenerative medicine. Before that, he spent 10 years as a sell-side equity analyst, most recently at ING. He also previously served as financial controller for Onyx Pharmaceuticals.

He holds a degree in microbiology from the University of Kent.


Biotech firm Taligen Therapeutics said that it has appointed Alnylam Pharmaceuticals CEO John Maraganore to its board of directors.

Before taking the helm of Alnylam, Maraganore was senior vice president of product development at Millennium Pharmaceuticals. He has also held roles at Biogen (now Biogen Idec) and Angiomax.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.